16 September 2026 editorial review · Trial
GTT@Home: home oral glucose tolerance testing for T1D screening: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Added43kg weight threshold and distinct minimum age12 for recent-onset stage3 cohort; endpoint is measurement agreement not disease prevention.
Registry: NCT07155252. Registered endpoint checked: Accuracy of GTT@Home (up to 4 weeks from enrollment). Eligibility check: Registry age 8 Years to 45 Years; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.